
The Zhitong Finance App learned that on November 14, at the 2026 Innovative Drug High Quality Development Conference held in Suzhou, the 2026 National Basic Medical Insurance Drug Catalogue and the Commercial Health Insurance Innovative Drug Catalogue adjustment results were officially announced. 107 new drugs were added to the basic medical insurance catalogue, of which 51 were first-class innovative drugs, a record high. 12 new drugs were added to the commercial insurance innovative drug catalogue, and the total number of drugs in the catalogue increased to 28. At the same time, two drugs that previously entered the commercial insurance innovative drug list were further included in basic medical insurance this year, and CAR-T products also achieved basic medical insurance admission for the first time.
Judging from this round of medical insurance catalogue adjustments, a number of major innovative drugs were “approved and included that year.” The new drugs cover various clinical fields such as tumors, rare diseases, chronic diseases, mental illness, and pediatric medication, and focus on incorporating innovative drugs with clear clinical benefits and excellent economic evaluation.
After the adjustment, the total number of drugs included in the national medical insurance drug catalogue reached 3,331, including 1,935 Western medicines and 1,396 proprietary Chinese medicines.
The analysis points out that as innovative drugs continue to accelerate their entry into medical insurance, the commercialization process of the industry is expected to accelerate further. The dynamic adjustment mechanism for the medical insurance catalogue has been continuously improved to help shorten the time from approval for marketing of innovative drugs to entry into medical insurance, improve the accessibility of medication for patients, and is also expected to further promote the commercialization of innovative drugs.
It is worth noting that with the implementation of the medical insurance catalogue, the focus of policy support for innovative drugs is being further extended from medical insurance admission to in-hospital equipment and clinical use. Zhang Ke, director of the National Health Insurance Administration, said that it will promote “pre-admission” of new drugs in the catalogue and will carry out “face-to-face medicine, medicine, insurance, and learning” activities in 12 cities to promote innovative technology and the latest achievements into hospitals, pharmacies, prescriptions, and classrooms.
Meanwhile, the National Health Commission, the National Health Insurance Administration, the State Administration of Traditional Chinese Medicine, and the National Administration for Disease Control and Prevention recently jointly issued relevant notices to further improve the safe and rational use of innovative drugs. The notice requires medical institutions above level 2 to optimize the process of entering hospitals for innovative drugs and promptly include them in the medication catalogue according to diagnosis and treatment requirements. Class 1 new drugs in the two catalogs are not included in the “one product, two regulations”, and are not included in performance monitoring indicators such as the increase in the average cost of drugs for outpatients and hospitalizations. For cases where innovative drugs in the medical insurance catalogue are not suitable for payment according to disease type payment standards, special cases can be declared for individual discussions, which helps to further unblock clinical use and payment channels for innovative drugs.
Judging from industry trends, the innovative pharmaceutical industry is gradually entering a stage of development that places equal emphasis on “R&D innovation+commercialization”. With the gradual establishment of a “dual catalog” bridging mechanism for medical insurance and commercial insurance, and the continuous optimization of innovative drug entry and clinical use, pharmaceutical companies with strong innovation capabilities, outstanding commercialization capabilities, and major products entering the marketing period one after another are expected to take the lead in benefiting.
CITIC Securities released a research report stating that the national health insurance negotiations will continue to support innovative drugs and focus on increasing commercialization in 2027. As entry and renewal rules are further improved, long-term commercialization expectations for innovative drugs have become more clear. At the same time, hospital admission and payment facilities are progressing simultaneously, which is expected to speed up the transformation of catalogue entry into prescription volume. The bank believes that CAR-T is entering basic medical insurance for the first time, and the accessibility of cell therapy is expected to improve. Furthermore, the expansion of ADC medical insurance payment coverage to more cutting-edge treatment lines and more cancer types is expected to drive domestic sales growth.
Guojin Securities released a research report stating that the dual catalogue broadens payment coverage for patients, and the hospital admission policy is expected to speed up the transformation of catalogue entry into in-hospital prescriptions. We are optimistic about the number of innovative domestic pharmacies released in 2027, focusing on new products with clear clinical needs, and there is still room for improvement in hospital coverage, as well as progress in commercial insurance coverage and actual compensation for high-value treatments.
Related concept stocks
Cinda Biotech (01801): According to the company's announcement, seven of its innovative products were successfully included in the 2026 edition of the National Medical Insurance Drug Catalogue, covering diseases with heavy social burdens such as tumors (bowel cancer, kidney cancer, hematoma), cardiovascular metabolism, and autoimmunity. These include products that were first covered by medical insurance, such as mazedulepam, piconcibalizumab, and ipimumab N01, as well as products with new indications of cindilimab and pitobutinib included in medical insurance. As of this adjustment, the company's lineup of innovative drugs included in the national health insurance catalogue has been expanded to 17 models.
Dongyangyang Pharmaceutical (06887): The sodium-glucose transporter 2 inhibitor (SGLT-2 inhibitor) and the Class 1 innovative drug Ologlicline capsules (trade name: Dongzean®) were successfully included in the 2026 edition of the National Medical Insurance Drug List. The product was approved for marketing in January 2026. It can be used as a single drug or in combination with metformin to improve blood sugar control in adult type 2 diabetics and achieve “approved that year and included in that year” medical insurance catalogue.
Fu Hong Han Lin (02696): The company's Hans form (slulilizumab injection) was included in the 2026 edition of the national medical insurance drug catalogue for the first time, covering all of its indications approved for marketing in China; futunin (vorbesilil citrate capsules) added a second indication to the national medical insurance drug catalogue.
Medication Juno-B (02126): The company's core product, Benodat (Ricky Orense injection), was officially included in the 2026 edition of the national basic medical insurance drug catalogue, covering the three indications of large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is worth noting that Benodat is the only CAR-T therapy product included in the national basic medical insurance drug catalogue this time, marking an important breakthrough in CAR-T access to basic medical insurance.